



Press release

Stockholm 22 November, 2017

Bactiguard's endotracheal tubes approved in India

The product approval for Bactiguard's endotracheal tubes has been announced by the Indian Ministry of Health & Family Welfare. This means that Bactiguard can offer its complete portfolio of products for effective and safe infection prevention in one of the largest and fastest growing markets in the world.

The Central Drugs Standard Control Organisation (CDSCO), under the Ministry of Health & Family Welfare, has announced the regulatory approval of Bactiguard's endotracheal tubes for infection prevention (BIP ETT and BIP ETT Evac) in India.

"Blood stream infections, respiratory and urinary tract infections are the most frequent and serious healthcare associated infections, especially in intensive care settings. We are therefore very pleased that we can now offer products to address all of those in India. A few months ago, our central venous catheters were approved and since a couple of years our urinary catheters are available on the market. The new approval means that we can offer more complete protection for the most vulnerable patients, which will save many lives and reduce suffering for both patients and their relatives", says Cecilia Edström, CFO.

Bactiguard's urinary catheter (BIP Foley Catheter) was launched in India in early 2016 and in August this year, the Ministry of Health & Family Welfare approved Bactiguard's central venous catheter (BIP CVC). Following the product approval for BIP ETT and BIP ETT Evac, Bactiguard can now offer its complete range of infection prevention products in the Indian market.

For further information, please contact:

Cecilia Edström, SVP Sales and New business, cell phone: +46 72 226 23 28

About Bactiguard

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission we develop and supply infection protection solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner CR Bard, urinary catheters with Bactiguard's



coating are market leading in the USA and Japan. Bactiguard's own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.

Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 60 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about how Bactiguard saves lives on www.bactiguard.com